Oryzon Genomics SA (ORY) AI Stock Analysis

• Market Cap: €252.72M
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: 36.23%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 79,887,700
• 10 Day Avg. Volume: 2,474,153
• 30 Day Avg. Volume: 1,678,358
• PEG Ratio: -7.53
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 12.25
• P/FCF Ratio: -6.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €12.00
• Price Target Upside: 272.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: €3.50 ▲(8.70% Upside)

Oryzon Genomics SA's stock score is primarily influenced by its financial performance, which shows typical growth patterns for a biotech firm but also highlights consistent losses and rising debt. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. The absence of earnings call data and corporate events means these factors do not impact the score.

Positive Factors

Strong equity position

A high equity ratio gives structural balance-sheet stability that supports continued R&D investment and absorbs operating volatility typical of clinical-stage biotechs. This reduces immediate insolvency risk and improves capacity to fund trials before product revenues materialize.

High gross margins

Sustainably high gross margins signal attractive unit economics for eventual product commercialization. If clinical programs succeed, these margins provide operating leverage, allowing incremental revenue to flow to the bottom line faster and improving long-term profitability prospects.

Focused epigenetics pipeline

A concentrated R&D focus on epigenetic targets creates deep domain expertise and potential first-mover advantages in niche indications. Structured pipeline focus can attract strategic partnerships, licensing, and targeted capital, increasing probability of lasting commercial or deal value upon clinical success.

Negative Factors

Consistent negative free cash flow

Persistent negative free cash flow forces reliance on external financing to sustain operations and trials. Over the medium term this creates dilution and constrains strategic choices, raising execution risk if capital markets tighten or fundraising terms deteriorate before revenue generation.

Rising leverage

An uptick in leverage raises fixed obligations and refinancing exposure, reducing financial flexibility. For a loss-making clinical-stage biotech, higher debt increases cash burn sensitivity to interest and repayment schedules, which can limit R&D scope and heighten solvency risk over months.

Ongoing net losses and recent revenue decline

Sustained net losses combined with a recent revenue dip weaken the path to self-sustaining operations. This pressurizes cash reserves and margins, increases dependency on external funding, and makes achieving breakeven more uncertain absent clear clinical milestones or new revenue sources.

Oryzon Genomics SA Business Overview & Revenue Model

Company Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

How the Company Makes Money

Oryzon Genomics SA generates revenue primarily through collaborative agreements with other pharmaceutical companies, licensing its proprietary technology, and conducting research and development projects. The company forms strategic partnerships to co-develop and commercialize its drug candidates, which may involve upfront payments, milestone payments, and royalties on future sales. Oryzon also seeks funding through government grants and research subsidies to support its ongoing R&D efforts. These partnerships and collaborations are crucial for providing the financial resources needed to advance their clinical trial programs and ultimately bring their therapeutics to market.

Oryzon Genomics SA Financial Statement Overview

Summary

Oryzon Genomics SA is experiencing typical growth and development phases for a biotech firm, with high gross margins but consistent net losses and negative cash flows. The strong equity position offers some stability, but rising debt levels and continuous losses are concerning.

Income Statement

Oryzon Genomics SA shows improving revenue presence with a significant increase from zero in 2020 to 2024, however, revenue has declined in the past year. Gross profit margins are high, but the company is operating at a net loss, impacting the net profit margin and EBIT/EBITDA margins negatively. The company appears to be focusing on growth and development, typical for the biotechnology sector, yet consistent losses are a concern.

Balance Sheet

The balance sheet indicates a strong equity position with a high equity ratio, suggesting stability. However, the debt-to-equity ratio has increased slightly, indicating rising leverage. Return on equity is currently negative due to ongoing losses. Overall, the company maintains a solid asset base, but increasing debt levels should be monitored.

Cash Flow

Cash flows reveal consistent negative free cash flow, reflecting heavy investment and operating cash outflows. The operating cash flow to net income ratio is negative due to losses. Financing activities are positive, suggesting reliance on external funding. Continuous negative cash flow is a risk, but typical for growth-focused biotech firms.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.36M	7.36M	0.00	0.00	10.62M	9.52M
Gross Profit	11.13M	7.06M	13.95M	15.23M	9.87M	8.99M
EBITDA	-1.69M	-4.43M	-4.43M	-5.35M	-6.88M	-4.16M
Net Income	-4.04M	-3.67M	-3.35M	-4.23M	-4.69M	-3.40M
Balance Sheet
Total Assets	138.35M	108.72M	106.90M	103.70M	95.38M	94.11M
Cash, Cash Equivalents and Short-Term Investments	31.11M	5.62M	12.26M	21.32M	28.72M	39.60M
Total Debt	13.73M	16.21M	13.69M	17.44M	17.52M	13.53M
Total Liabilities	24.13M	21.67M	25.13M	31.13M	24.12M	18.18M
Stockholders Equity	114.22M	87.04M	81.77M	72.57M	71.26M	75.93M
Cash Flow
Free Cash Flow	0.00	-13.40M	-15.08M	-16.12M	-15.39M	-14.04M
Operating Cash Flow	0.00	-5.69M	-574.96K	-1.85M	-3.63M	-4.82M
Investing Cash Flow	0.00	-7.81M	-14.50M	-14.27M	-11.72M	-9.08M
Financing Cash Flow	0.00	6.87M	6.02M	8.71M	4.12M	18.38M

Oryzon Genomics SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Positive. The current price of 3.22 is above the 20-day moving average (MA) of 3.21, above the 50-day MA of 3.17, and above the 200-day MA of 2.96, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.80 is Neutral, neither overbought nor oversold. The STOCH value of 56.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ORY.

Oryzon Genomics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	74 Outperform	€3.67B	30.82	20.70%	1.50%	-9.39%	-25.92%
RJF	65 Neutral	€220.51M	50.28	2.03%	1.91%	-1.19%	-54.66%
PHM	57 Neutral	€1.43B	42.58	17.22%	1.04%	7.35%	5375.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORY	48 Neutral	€252.72M	-76.49	-2.87%	―	―	36.23%
ATRY	42 Neutral	€228.70M	-9.29	-9.43%	―	15.90%	37.03%